At the J.P. Morgan Healthcare Conference in San Francisco, Teva has provided a timeline for its much-talked-about long-acting injectable olanzapine candidate, after wrapping up a Phase III clinical trial with data that the firm believes will give it a major advantage over its competitors. The product, dubbed 'Night And Day', is set for a 2026 launch, marking a significant milestone in the treatment of conditions requiring long-acting antipsychotic medication. Teva's announcement underscores the company's commitment to advancing psychiatric treatment options and its confidence in the efficacy and market potential of its olanzapine formulation.
Teva Announces 2026 Launch for 'Night And Day' Olanzapine Long-Acting Injectable

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.
Related News
Sources
Teva Plots Out 2026 Launch For 'Night And Day' Olanzapine Long-Acting Injectable
insights.citeline.comJan 14, 2025